严重脑出血与脑室内出血后初始重度残疾存活者的一年功能恢复轨迹及恢复相关因素
该事后分析汇总CLEAR-III与MISTIE-III两项3期试验的个体数据,纳入715例第30天改良Rankin量表(mRS)4~5分的脑出血(ICH)和脑室内出血(IVH)存活者,1年内129例(18%)死亡、308例(43%)恢复至mRS 0~3。糖尿病、入院美国国立卫生研究院卒中量表(NIHSS)评分、严重白质疏松、急性缺血性卒中、胃造瘘及第30天持续性脑积水与未恢复相关,第30天ICH和IVH消退与恢复良好相关。
要点
- 715例初始重度残疾的ICH/IVH存活者中,1年内43%恢复至mRS 0~3,18%死亡。
- 第30天ICH消退(aOR 1.82)和IVH消退(aOR 2.19)与恢复良好相关。
- 基于30天事件的模型预测1年结局的AUC为0.87,优于仅用基线严重度因素的模型(AUC 0.76)。
核心结论
- 在初始功能结局差的严重ICH和IVH存活者中,超过40%在1年内恢复至良好结局。
- 住院期间事件与长期功能恢复强烈相关,可能是干预的潜在靶点。
- 避免早期悲观预后判断、将预后评估推迟至治疗之后,可能提高预测未来恢复的能力。
研究设计与样本
- 该研究为事后分析,汇总CLEAR-III与MISTIE-III两项3期试验的全部个体患者数据,来自美国、加拿大、欧洲和亚洲的多中心。
- 患者入组时间为2010年8月1日至2018年9月30日,随访1年。
- 999例入组患者中,排除13例第30天mRS缺失者后,724例以第30天mRS 4~5分存活;再排除9例1年mRS缺失者,最终汇总队列为715例(71.6%)第30天mRS 4~5分患者。
- 数据分析时间为2019年7月至2022年1月。
- CLEAR-III参与者随机接受脑室内阿替普酶与安慰剂;MISTIE-III参与者随机接受立体定向血肿溶栓与标准内科治疗。
主要发现
- 715例存活者中417例(58%)为男性,总体平均(SD)年龄为60.3(11.7)岁;174例(24.3%)为黑人,491例(68.6%)为白人,49例(6.9%)为其他种族;98例(13.7%)为西班牙裔。
- 至1年时,129例(18%)死亡,308例(43%)达到mRS 0~3。
- 合并队列校正模型中,糖尿病(aOR 0.50;95%CI 0.26-0.96)、NIHSS(aOR 0.93;95%CI 0.90-0.96)、严重白质疏松(aOR 0.30;95%CI 0.16-0.54)、松果体移位(aOR 0.87;95%CI 0.76-0.99)、急性缺血性卒中(aOR 0.44;95%CI 0.21-0.94)、胃造瘘(aOR 0.30;95%CI 0.17-0.50)及第30天持续性脑积水(aOR 0.37;95%CI 0.14-0.98)与未恢复相关。
- 第30天ICH消退(aOR 1.82;95%CI 1.08-3.04)和IVH消退(aOR 2.19;95%CI 1.02-4.68)与恢复至良好结局相关。
- CLEAR-III模型中,脑灌注压低于60 mmHg(aOR 0.30;95%CI 0.13-0.71)、脓毒症(aOR 0.05;95%CI 0.00-0.80)和延长机械通气(aOR 0.96;95%CI 0.92-1.00,每天)为不良结局的额外相关因素;MISTIE-III中需颅内压监测(aOR 0.35;95%CI 0.12-0.98)亦为额外相关因素。
临床怎么用
- 作者认为,避免早期悲观预后判断并将预后评估推迟至治疗之后,可能提高预测未来恢复的能力。
- 作者认为住院期间事件与长期功能恢复强烈相关,可能是干预的潜在靶点。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Patients who survive severe intracerebral hemorrhage (ICH) and intraventricular hemorrhage (IVH) typically have poor functional outcome in the short term and understanding of future recovery is limited. OBJECTIVE: To describe 1-year recovery trajectories among ICH and IVH survivors with initial severe disability and assess the association of hospital events with long-term recovery. DESIGN, SETTING, AND PARTICIPANTS: This post hoc analysis pooled all individual patient data from the Clot Lysis: Evaluating Accelerated Resolution of Intraventricular Hemorrhage phase 3 trial (CLEAR-III) and the Minimally Invasive Surgery Plus Alteplase for Intracerebral Hemorrhage Evacuation (MISTIE-III) phase 3 trial in multiple centers across the US, Canada, Europe, and Asia. Patients were enrolled from August 1, 2010, to September 30, 2018, with a follow-up duration of 1 year. Of 999 enrolled patients, 724 survived with a day 30 modified Rankin Scale score (mRS) of 4 to 5 after excluding 13 participants with missing day 30 mRS. An additional 9 patients were excluded because of missing 1-year mRS. The final pooled cohort included 715 patients (71.6%) with day 30 mRS 4 to 5. Data were analyzed from July 2019 to January 2022. EXPOSURES: CLEAR-III participants randomized to intraventricular alteplase vs placebo. MISTIE-III participants randomized to stereotactic thrombolysis of hematoma vs standard medical care. MAIN OUTCOMES AND MEASURES: Primary outcome was 1-year mRS. Patients were dichotomized into good outcome at 1 year (mRS 0 to 3) vs poor outcome at 1 year (mRS 4 to 6). Multivariable logistic regression models assessed associations between prospectively adjudicated hospital events and 1-year good outcome after adjusting for demographic characteristics, ICH and IVH severity, and trial cohort. RESULTS: Of 715 survivors, 417 (58%) were male, and the overall mean (SD) age was 60.3 (11.7) years. Overall, 174 participants (24.3%) were Black, 491 (68.6%) were White, and 49 (6.9%) were of other races (including Asian, Native American, and Pacific Islander, consolidated owing to small numbers); 98 (13.7%) were of Hispanic ethnicity. By 1 year, 129 participants (18%) had died and 308 (43%) had achieved mRS 0 to 3. In adjusted models for the combined cohort, diabetes (adjusted odds ratio [aOR], 0.50; 95% CI, 0.26-0.96), National Institutes of Health Stroke Scale (aOR, 0.93; 95% CI, 0.90-0.96), severe leukoaraiosis (aOR, 0.30; 95% CI, 0.16-0.54), pineal gland shift (aOR, 0.87; 95% CI, 0.76-0.99]), acute ischemic stroke (aOR, 0.44; 95% CI, 0.21-0.94), gastrostomy (aOR, 0.30; 95% CI, 0.17-0.50), and persistent hydrocephalus by day 30 (aOR, 0.37; 95% CI, 0.14-0.98) were associated with lack of recovery. Resolution of ICH (aOR, 1.82; 95% CI, 1.08-3.04) and IVH (aOR, 2.19; 95% CI, 1.02-4.68) by day 30 were associated with recovery to good outcome. In the CLEAR-III model, cerebral perfusion pressure less than 60 mm Hg (aOR, 0.30; 95% CI, 0.13-0.71), sepsis (aOR, 0.05; 95% CI, 0.00-0.80), and prolonged mechanical ventilation (aOR, 0.96; 95% CI, 0.92-1.00 per day), and in MISTIE-III, need for intracranial pressure monitoring (aOR, 0.35; 95% CI, 0.12-0.98), were additional factors associated with poor outcome. Thirty-day event-based models strongly predicted 1-year outcome (area under the receiver operating characteristic curve [AUC], 0.87; 95% CI, 0.83-0.90), with significantly improved discrimination over models using baseline severity factors alone (AUC, 0.76; 95% CI, 0.71-0.80; P < .001). CONCLUSIONS AND RELEVANCE: Among survivors of severe ICH and IVH with initial poor functional outcome, more than 40% recovered to good outcome by 1 year. Hospital events were strongly associated with long-term functional recovery and may be potential targets for intervention. Avoiding early pessimistic prognostication and delaying prognostication until after treatment may improve ability to predict future recovery.
引用
- Shah VA, Thompson RE, Yenokyan G, et al. One-Year Outcome Trajectories and Factors Associated with Functional Recovery Among Survivors of Intracerebral and Intraventricular Hemorrhage With Initial Severe Disability. JAMA Neurol. 2022. PMID: 35877105. doi:10.1001/jamaneurol.2022.1991
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。